Reviva Pharmaceuticals Holdings, Inc.RVPHNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank57
3Y CAGR-8.2%
5Y CAGR+118.4%
Year-over-Year Change
Research and development spending
3Y CAGR
-8.2%/yr
vs +111.5%/yr prior
5Y CAGR
+118.4%/yr
Recent deceleration
Acceleration
-119.8pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
49.6x
Strong expansion
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $14.65M | -36.0% |
| 2024 | $22.91M | -27.1% |
| 2023 | $31.42M | +65.8% |
| 2022 | $18.95M | +290.5% |
| 2021 | $4.85M | +1543.8% |
| 2020 | $295150.00 | +50.8% |
| 2019 | $195744.00 | -79.3% |
| 2018 | $946301.00 | - |